Publications by authors named "Harald Polzer"

Claim this Profile
T
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Maike Roas, Binje Vick, Marc-André Kasper, Marina Able, Harald Polzer

Blood· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Andreas Sellmer, Bernadette Pilsl, Mandy Beyer, Herwig Pongratz, Lukas Wirth, Harald Polzer

Eur J Med Chem· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The target landscape of clinical kinase drugs.
Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm, Harald Polzer, Binje Vick

Science· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.
Nadine Sandhöfer, Julia Bauer, Katrin Reiter, Annika Dufour, Maja Rothenberg, Harald Polzer

Sci Rep· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microenvironmental hypoxia regulates FLT3 expression and biology in AML.
Silvia Sironi, Michaela Wagner, Alexander Kuett, Heidrun Drolle, Harald Polzer

Sci Rep· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Hanna Janke, Friederike Pastore, Daniela Schumacher, Tobias Herold, Karl-Peter Hopfner, Harald Polzer

PLoS One· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Sabrina Opatz, Harald Polzer, Tobias Herold, Nikola P Konstandin, Bianka Ksienzyk

Blood· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Harald Polzer, Hanna Janke, Diana Schmid, Wolfgang Hiddemann, Karsten Spiekermann

Exp Hematol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Kristin Pietschmann, Hella Anna Bolck, Marc Buchwald, Steffi Spielberg, Harald Polzer

Mol Cancer Ther· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis